Table 1—

Main characteristics of clinical trials included in the meta-analysis

Study (11)*CharacteristicsComparatorDuration (weeks)Number R/CMean age (years)Mean A1C (%)Incident cases of cancer R/C
Nondiabetic subjects
    Trials on GSK Web site
100684Metabolic syndromePlacebo5243/47450/0
49653/330Plaque psoriasisPlacebo521,181/382443/1
49653/331Plaque psoriasisPlacebo52706/325450/1
49653/334Insulin resistantPlacebo52178/177684/3
49653/392Insulin resistantMetformin5216/15560/0
49653/131Insulin resistantPlacebo2639,427480/0
49653/452Multiple sclerosisPlacebo2626/25420/1
ARA102198Rheumatoid arthritisPlacebo2649/49560/0
AVA100193Alzheimer's diseasePlacebo24394/124710/0
    Other published trials
CarrHIV infectionPlacebo4853/55451/0
SidhuCoronary artery diseasePlacebo4846/46620/0
SilicHIV infectionMetformin4830/30420/0
van WijkHIV infectionMetformin2619/20470/0
CollHIV infectionMetformin2615/16480/0
CavalcantiHIV infectionPlacebo2448/48470/0
BaillargeonPCOSPlacebo2442/30270/0
LemayPCOSNone2415/13240/0
Type 2 diabetic patients
    Trials on GSK Web site
49653/048 (ADOPT)MonotherapyGlyburide2081,456/1,441567.363/71
49653/048 (ADOPT)MonotherapyMetformin2081,456/1,454577.363/67
49653/080MonotherapyGlyburide156104/99569.11/3
49653/097MonotherapyGlyburide148122/120568.91/4
49653/135Combined therapyPlacebo104116/111687.44/7
49653/211NYHA-II, mono-combinedPlacebo52110/11464NR2/3
49653/020MonotherapyGlyburide52384/203608.23/0
AVM100264Combined therapySulfonylureas52294/302598.02/1
712753/008Combined therapyNone48284/13555NR3/0
49653/137Combined therapyGlyburide32204/185598.42/4
BRL49653/185Mono-combinedNone32563/142597.44/2
SB-712753/003Combined therapyPlacebo32254/272597.20/1
SB-712753/007Monotherapy, OLMetformin32159/154597.20/0
SB-712753/007Combined therapy, OLNone32155/154597.20/0
49653/128Combined therapyPlacebo2839/38589.60/0
49653/134Combined therapyPlacebo28561/276558.70/2
SB-797620/004MonotherapyGlimepiride28232/225539.01/0
49653/024MonotherapyPlacebo26774/185578.95/1
49653/044Combined therapyPlacebo2671/34549.60/0
49653/079MonotherapyGlyburide26104/106589.21/0
49653/079Combined therapyPlacebo2699/106589.22/0
49653/082Combined therapyPlacebo26212/107569.10/0
49653/085Combined therapyPlacebo26138/13961NR1/0
49653/093MonotherapyMetformin26107/109598.70/0
49653/093Combined therapyPlacebo26106/109598.70/0
49653/094Combined therapyPlacebo26232/116588.80/0
49653/095Combined therapyPlacebo26196/96589.01/0
49653/096Combined therapyPlacebo26232/115609.12/0
49653/109MonotherapyGlipizide2652/25538.00/0
49653/125Combined therapy, OLNone26175/173568.90/0
49653/127Combined therapyPlacebo2656/58609.00/2
49653/136Combined therapyPlacebo26148/143658.22/0
49653/145Combined therapyNone26231/242618.61/0
49653/147Combined therapyPlacebo2689/88549.10/0
49653/162Combined therapyPlacebo26168/172608.02/0
49653/234Combined therapyPlacebo26116/61638.11/0
49653/390Combined therapyNone2633/30NRNR1/0
49653/369MonotherapyGlyburide2625/24526.80/0
49653/132Combined therapyPlacebo24442/112599.81/1
49653/347Combined therapyPlacebo24418/212539.00/1
49653/015Combined therapyPlacebo24395/198619.24/0
49653/284Combined therapyPlacebo24382/384558.01/0
SB-712753/002Combined therapyPlacebo24288/280587.51/0
49653/090MonotherapyPlacebo24228/75598.81/0
49653/325Combined therapyPlacebo24196/195538.00/1
SB-712753/009Combined therapyPlacebo24162/160578.72/0
AVD102209Combined therapyPlacebo24132/131569.60/0
49653/143Combined therapyPlacebo24121/124529.21/0
49653/207Children monotherapyMetformin2499/101148.00/0
49653/282Combined therapyGlyburide2469/72607.60/0
    Other published trials
KoCombined therapyInsulin5256/56589.60/0
Derosa (a)Combined therapyGlimepiride5249/50538.00/0
Derosa (b)Combined therapyPioglitazone5248/48559.00/0
Derosa (c)MonotherapyPioglitazone5245/42548.10/0
RahmanMonotherapyPlacebo5211/11477.50/0
KellyCombined therapyGlyburide2620/16607.60/0
ReynoldsMonotherapyPlacebo268/10499.20/0
OsmanMonotherapy, PTCAPlacebo268/8559.60/0
ZhouCombined therapyPlacebo24442/112569.80/0
GoldbergMonotherapyPioglitazone24369/366567.50/0
WeissmanCombined therapyPlacebo24358/351558.00/0
AgrawalCombined therapyNone24288/280587.50/0
DaileyCombined therapyPlacebo24181/184578.10/1
GarberCombined therapyGlyburide24158/160568.50/0
WangMono-combinedNone2435/35617.30/0
WongCombined therapyNone2426/26627.20/0
JungCombined therapyMetformin2415/15579.10/0
Total39.216,332/12,52255.38.1124/178
  • *

    * See Appendix for references.

  • Trials with multiple comparators. ADOPT, A Diabetes Outcome Progression Trial; mono-combined, monotherapy or combined therapy; NR, not reported; NYHA-II, New York Heart Association, Class II; OL, open label; PCOS, polycystic ovary syndrome; PTCA, percutaneous transluminal coronary angioplasty; R/C, rosiglitazone versus comparator.